Japan Mrna Therapeutics Market Size & Outlook, 2023-2030
Japan mrna therapeutics market, 2021-2030 (US$M)
Related Markets
Japan mrna therapeutics market highlights
- The Japan mrna therapeutics market generated a revenue of USD 654.6 million in 2023 and is expected to reach USD 1,812.6 million by 2030.
- The Japan market is expected to grow at a CAGR of 15.7% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating application in 2023.
- Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
| Market revenue in 2023 | USD 654.6 million |
| Market revenue in 2030 | USD 1,812.6 million |
| Growth rate | 15.7% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
Other key industry trends
- In terms of revenue, Japan accounted for 5.6% of the global mrna therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,786.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Market Scope
MRNA Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan mrna therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Japan mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The Japan mRNA therapeutics market is moderately competitive, with the presence of a few major companies offering raw materials to mRNA synthesis providers, including FUJIMOTO CHEMICALS CO., LTD.; Natias Co., Ltd.; AMBiS Corp.; AnGes, Inc.; and Meridian Bioscience. Several Japanese government, academic, and research institutes demand these raw materials for mRNA-based vaccines.
Hence, major players in the market are adopting several strategies, including mergers & acquisitions, partnerships & collaborations, to stay competitive. For instance, in March 2022, Mitsui Chemicals, Inc. acquired the majority stake in Natia, Inc., a Japanese R&D startup involved in mRNA synthesis.
Reasons to subscribe to Japan mrna therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan mrna therapeutics market databook
-
Our clientele includes a mix of mrna therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan mrna therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan mrna therapeutics market size, by application, 2021-2030 (US$M)
Japan MRNA Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
